Hamstra says that shorter regimens of radiotherapy for men whose prostates remained in tact post-surgery proved to be noninferior when compared to longer regimens. He adds that these shorter regimens are more convenient for patients, as well as more cost effective.
Daniel Hamstra, MD, PhD, radiation oncologist, Texas Center for Proton Therapy, Texas Oncology, discusses radiotherapy in different doses as a treatment for prostate cancer. Hamstra says that shorter regimens of radiotherapy for men whose prostates remained in tact post-surgery proved to be noninferior when compared to longer regimens. He adds that these shorter regimens are more convenient for patients, as well as more cost effective.
Hamstra says the study titled RTOG 0415, conducted with roughly 1000 patients in the United States, compared an 8 week regimen of radiotherapy to a regimen of 5.5 weeks and found that the outcomes were "virtually identical" for recurrence and long term side effects. Hamstra adds that there was a very small increase in gastrointestinal side effects. The CHIP trial, conducted in Great Britain with over 3000 patients, resulted with similar data.
FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC
May 10th 2024The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.
Read More
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More